Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
November 16, 2017 08:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide additional...
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients
October 02, 2017 07:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has...
Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
September 14, 2017 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that a new...
Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury’s “NewsMakers” Conference
August 15, 2017 07:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that the Company will present...
Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis
August 07, 2017 06:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has completed...
Innovation Pharmaceuticals Phase 2 PoC Trial for Inflammatory Bowel Disease Achieves Induction of Remission in a Majority of Patients Treated with Brilacidin
July 13, 2017 16:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., July 13, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that a majority of patients...
Innovation Pharmaceuticals Completes Treatments in Phase 2 PoC Trial for Induction of Remission in Inflammatory Bowel Disease; Topline Results with Endoscopic Response to Be Presented July 13, 2017
June 26, 2017 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient treatment has...
Innovation Pharmaceuticals Name and Ticker Change Effective, Replay of Shareholder Conference Call Available
June 09, 2017 09:15 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., June 09, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, Inc. (OTCQB:IPIX) (“the Company”), an emerging biopharmaceutical company, is pleased to announce that the Company’s name...
Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc.
June 07, 2017 16:05 ET
|
Cellceutix Corporation
BEVERLY, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), an emerging biopharmaceutical company, is pleased to announce to shareholders, and the public...
Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting
May 30, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to share further data supporting the p53 mechanism of action of Kevetrin and its...